Prostate Cancer Clinical Trial
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.
The investigators propose to evaluate a novel second-generation low-molecular-weight prostate specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL, for detection of primary and metastatic prostate cancer. 18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
Primary Objectives: The investigators propose to evaluate this PET agent for four different prostate cancer clinical scenarios.
detection of clinically significant high-grade prostate cancer and initial staging
detection of sites of recurrence in the setting of biochemical recurrence after definitive prostatectomy
detection of advanced androgen-resistant metastatic prostate cancer, and
detection of clinically significant prostate cancer in very low to intermediate risk primary prostate cancer
Evaluate the performance of 18F-DCFPyL PET and MRI whole body DWI for detection of local-nodal and distant metastatic disease on initial staging compared to conventional imaging modalities (CT and bone scintigraphy).
Correlate 18F-DCFPyL PET standardized-uptake values (SUV) and MRI parameters with PSMA expression by prostatectomy pathology IHC.
Evaluate the specificity of 18F-DCFPyL PET for differentiating primary prostate cancer versus non-malignant prostate lesions (BPH, prostatitis).
Comparison of whole body low-dose CT and whole body MRI derived PET SUV-quantitation.
Evaluate the performance of dedicated pelvic 18F-DCFPyL PET/MRI with dynamic PET acquisition and multi-parametric MRI for differentiation of urine versus recurrent malignancy in the prostatectomy bed.
Evaluate the contribution of whole body MRI DWI obtained from PET/MRI to improve the diagnostic performance of 18F-DCFPyL PET/CT and PET/MRI for metastatic prostate cancer lesion detection.
Assess the quantitative accuracy of PET-derived standardized uptake value (SUV)-based parameters in 18F-DCFPyL PET obtained from PET/MRI versus PET/CT.
Assess the quantitative reproducibility of 18F-DCFPyL PET/CT derived-SUV values in normal organ and metastatic tumor lesions.
Evaluate the ability of 18F-DCFPyL PET to improve detection of clinically significant primary prostate cancer in men with very low to intermediate risk prostate cancer under active surveillance or watchful waiting.
Update: As of July 2022 verification, the investigators are no longer enrolling into sub-studies 1 and 2.
Prostate cancer pathologically proven by prostate biopsy (newly diagnosed for Sub-Study 1 and 4)
Prostate biopsy histology grade â‰¥ Gleason 1, 6, 3+4, or 4+3; positive biopsy >2 cores
Any PSA permitted
Two consecutive rising PSA values (Sub-Study 3 only)
Castrate-levels of testosterone - total testosterone < 50 ng/dL (Sub-Study 3 only)
Patients considered as candidates for and medically fit to undergo prostatectomy
At least 7 days after most recent prostate biopsy
Imaging evidence of suspected metastatic disease, including CT, bone scan, MRI, ultrasound or other PET modalities (Sub-Study 3 only)
New diagnosis of prostate cancer undergoing additional biopsy evaluation (Sub--Study 4 only)
Karnofsky performance status of at least 70 (Sub-Study 4 only)
General health and anatomy suitable to undergo transrectal ultrasound-MRI fusion biopsy of the identified lesions and standard 12 core sextent biopsy (Sub-Study 4 only)
Prior pelvic external beam radiation therapy or brachytherapy
Chemotherapy for prostate cancer
Androgen deprivation therapy for prostate cancer
Investigational therapy for prostate cancer (Sub-Study 3 Only)
Unable to lie flat during or tolerate PET/CT
Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
No prostatectomy scheduled more than 12 hours post imaging (Sub-Study 1 only)
Serum creatinine > 2 time the upper limit of normal
Total bilirubin > 3 times the upper limit of normal
Liver Transaminases > 5 times the upper limit of normal
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Madison Wisconsin, 53792, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.